期刊文献+

Wnt信号通路与慢性粒细胞白血病 被引量:1

Wnt Signaling Pathway and Chronic Myelogenous Leukemia
下载PDF
导出
摘要 慢性粒细胞白血病作为血液系统的恶性增殖性肿瘤,其主要发病机制为BCR-ABL1融合基因形成,因此针对BCR-ABL1基因的靶向药物TKI为其治疗带来了希望,但TKI无法完全消除CML患者体内的LSCs,CML患者容易出现TKI药物耐药及治疗后复发。随着Wnt信号通路在实体瘤中的应用,大量研究发现Wnt信号通路同样在CML中起到重要作用,我们就Wnt信号通路对CML的影响作一综述。 As a type of cancer that starts in certain blood-forming cells of the bone marrow,chronic myeloid leukemia(CML)is caused by the formation of an abnormal gene called BCR-ABL1.The targeted medicine TKI for BCR-ABL1 has great effect on treating CML:however,TKI is not able to completely remove the leukemia stem cells(LSCs)in CML patients,which will lead to drug resistance and leukemia relapse.With the application of Wnt signaling pathway in regulating stem cell function,many studies have found that it also plays an important role in treating CML.In this paper,we reviewed the impact of Wnt signaling pathway on CML therapy.
作者 侯艳 李文倩 冯建明 艾国 解友邦 华青措 赵长明 HOU Yan;LI Wenqian;FENG Jianming;AI Guo;XIE Youbang;HUA Qingcuo;ZHAO Changming(Graduate School,Qinghai University,Xi’ning 810016,China;Department of Blood Rheumatology,Qinghai Provincial People's Hospital,Xi’ning 810007,China)
出处 《肿瘤防治研究》 CAS CSCD 2019年第2期174-177,共4页 Cancer Research on Prevention and Treatment
基金 青海省卫生计生委科研课题和适宜技术推广项目(2016-wjzdx-17) 青海省卫生计生委指导性科研课题(2016-wjzdx-16) 青海省人才"小高地"项目(青人才字[2014]12号) 国家临床重点专科建设项目(卫办医政函[2011]873号)
关键词 慢性粒细胞白血病 WNT信号通路 白血病干细胞 TKI Chronic myelogenous leukemia Wnt Leukemia stem cell TKI
  • 相关文献

参考文献2

二级参考文献29

  • 1Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- {alpha} treatment [J]. Blood, 2008, 111(3): 1039-43.
  • 2Ysebaert L, Chicanne G, Demur C, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced ctonogenic capacities and poor prognosis[ J ]. Leukemia, 2006, 20(7): 1211-6.
  • 3Bao F, Munker R, Lowery C, et al. Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR/ABL-positive leukemias [J]. Mol Diagn Ther, 2007, 11 (4): 239-45.
  • 4Huang H, He X. Wnt/beta-catenin signaling: new (and old) players and new insights [ J ]. Curr Opin Cell Biol, 2008, 20(2): 119-25.
  • 5Chim CS, Pang R, Fung TK, et al. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma [J]. Leukemia, 2007, 21 (12): 2527-36.
  • 6Roman-Gomez J, Cordeu L, Agirre X, et al. Epigenetic regulation of Writ-signaling pathway in acute lymphoblastic leukemia [J ]. Blood, 2007, 109(8): 3462-9.
  • 7Xu J, Suzuki M, Niwa Y, et al. Clinical significance of nuclear non- phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome [J]. Br J Haematol, 2008, 140 (4): 394-401.
  • 8Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML[J ]. N Engl J Med, 2004, 351(7): 657-67.
  • 9Ress A, Moelling K. Bcr is a negative regulator of the Wnt signalling pathway[J]. EMBO Rep, 2005, 6(11): 1095-100.
  • 10Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or highdose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial [J]. Blood, 2007, 109(12): 5143-50.

共引文献8

同被引文献16

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部